ClinicalTrials.gg
Not yet recruitingNCT07468227Updated Mar 12, 2026

Effect of Helfer Skin Tap and Vibration on Pain and Fear in Children During Intramuscular Injection

An interventional study of Helfer skin tab and Vibration Buzzy Bee in Pain and Fear, sponsored by Ege University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Ege University · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
5 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Pain by Ege University — 6 open to participants now, 7 under way, none of them phase 3. Pain · Ege University.

Planned enrollment
2nd of 30
186 · median 100
Started
2026
with 4 others
No phase
29 of 31
6 open now
Registered
26th of 31
by date

Among the 31 studies in Pain by Ege University, this one is the 2nd largest by planned enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2026, is one of 29 with no phase, and was the 26th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 31 studies in Pain by Ege University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 5 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Pain by Ege University, or all of them as a file.
02

Study summary

Intramuscular injection is one of the most common invasive procedures in childhood and is frequently associated with pain and fear. These negative experiences may affect children's attitudes toward healthcare and complicate nursing care. Therefore, using non-pharmacological methods is essential for promoting child-friendly services. This study aims to evaluate the effects of the Helfer Skin Tap and vibration techniques on pain and fear levels in children aged 5-10 years during intramuscular injections.

The study is designed as a parallel, three-arm randomized controlled trial conducted in the Pediatric Emergency Clinic of Ege University Hospital. Participants will be allocated by simple randomization to Helfer Skin Tap, vibration, or standard care. Sample size was calculated with G*Power 3.1 using a repeated-measures within-between interaction model with two time points (T0-T1), α=0.05, and power=0.80. Assuming a medium effect size (f=0.25) based on previous studies, at least 159 children are required. Allowing for 15% attrition, the final sample will include 186 participants (62 per group).

Data will be collected using a Child Information Form including sociodemographic characteristics and prior injection experiences. A Procedure Record Form will document randomization, assigned group, medication, dose, injection site, duration, child's position, and parental presence.

Pain and fear will be assessed immediately before (T0) and after (T1) the injection. Pain will be measured with the Wong-Baker FACES Pain Rating Scale (0-10) and fear with the Children's Fear Scale (0-4). Ratings will be obtained independently from the child, parent, and observing nurse.

The procedure will be video-recorded to enable objective evaluation of behavioral responses. Recordings will be scored by an independent blinded expert using standardized criteria. Videos will be used only for research purposes, with identifying features concealed, stored in coded format, and destroyed after study completion.

Read the detailed description

Intramuscular injection is one of the most frequently performed invasive procedures in childhood and is often associated with pain and fear. This situation can negatively affect children's healthcare experiences and cause difficulties for nurses in the care process. The use of non-pharmacological methods to reduce pain and fear is important for the development of child-friendly healthcare services. This project aims to evaluate the effect of the Helfer Skin Tap and vibration techniques used during intramuscular injections in children aged 5-10 years on the levels of pain and fear experienced by children.

The study was designed as a parallel, three-arm, randomized controlled experimental study at the Ege University Hospital Pediatric Emergency Clinic. Participants will be divided into three groups using simple random sampling; the first group will receive the Helfer Skin Tap technique, the second group will receive the vibration technique, and the third group will be the standard care control group. The sample size was calculated using the G*Power 3.1 program. Since the study involved three groups (Helfer Skin Tap, vibration, and control) and measurements at two time points (T0-T1), a 'within-between interaction' model was used for the analysis of variance for repeated measures. The Type I error level was set at α=0.05 and power (1-β)=0.80. Considering the effect sizes in similar intervention studies in the literature, a medium effect size (f=0.25) was assumed (Kurt et al., 2024). With these parameters, a total of at least 159 participants (approximately 53 children/group) are required. Considering possible losses, the sample size was planned to be 186 children (62 children/group) with a 15% increase. The Child Information Form, prepared by researchers in line with the relevant literature (Kurt et al., 2024), contains information on the children's sociodemographic characteristics (age, gender, height, weight, presence of other children in the family) and their experience with intramuscular injections (previous intramuscular injections, reactions to previous experiences). The Procedure Record Form will record randomization information, the study group to which the child was assigned (Helfer Skin Tap, vibration, or control), and technical information related to the injection (drug, dose, application site, procedure duration, child's position, and parent's presence during the procedure).

Children's pain and fear levels will be assessed at two time points: before the procedure (T0: immediately before the injection begins) and after the procedure (T1: immediately after the injection ends). Pain levels will be measured using the Wong-Baker FACES Pain Rating Scale (0-10 points), and fear levels will be measured using the Children's Fear Scale (CFS, 0-4 points). These assessments will be performed independently by the child, the parent, and the nurse observing the procedure.

Additionally, the intramuscular injection process will be video-recorded to objectively assess children's behavioral responses. The video recordings will be viewed by an expert evaluator who is not involved in the study and is unaware of the group assignments (blinded). The child's behavioral responses to pain and fear will be scored according to predefined standard evaluation criteria. Camera recordings will be used solely for scientific purposes; faces and identifying information will be concealed; recordings will be stored in coded form and will be destroyed after the study is completed.

03

Conditions studied

  • Pain
  • Fear

Browse trials for

Keywords

  • pediatric emergency
  • intramuscular injection
  • Helfer Skin Tap
  • vibration
  • randomized controlled trial
04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The child must be in the 5-10 age group
  • Intramuscular injection must be performed,
  • The child must be able to communicate in Turkish,
  • Verbal/written consent must be obtained from the parents/legal guardians

Exclusion criteria

Exclusion Criteria:

  • Known neurological disorders,
  • Inability to communicate cognitively,
  • Chronic pain syndrome
  • Acute and life-threatening clinical condition
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    Helfer Skin Tab

    Other: Helfer skin tab

  • Active comparator
    Vibration

    Device: Vibration Buzzy Bee

  • No intervention
    Control

Interventions

  • OtherHelfer skin tab

    A rhythmic and light tapping technique will be applied to the injection site before and during intramuscular injection.

  • DeviceVibration Buzzy Bee

    Short-term vibration will be applied to the injection site prior to injection, and vibration will be maintained during injection.

06

What researchers measure

Primary outcomes

  1. Fear level and incidence of intramuscular injections assessed by the Faces Scale for the Assessment of Anxiety

    The results will be collected using the Faces Scale for the Assessment of Anxiety. This scale is intended to numerically determine the child's level of fear related to the procedure.

    Time frame: Immediately before the injection begins, Immediately after the injection ends

  2. Pain level and incidence felt during intramuscular injection assessed by the Wong Baker Pain Scale

    The results will be collected using the Wong Baker Pain Scale. This scale is intended to numerically determine the child's level of pain related to the procedure.

    Time frame: Immediately before the injection begins, Immediately after the injection ends

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2026, 7 months later.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 7 months is below that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Mar 12, 2026
StartEst.
May 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
May 1, 2027
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07468227
Lead sponsor
Ege University
Responsible party
SEDA ARDAHAN SEVGİLİ (Asst. Professor, Ege University) — Principal investigator
First posted
Mar 12, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Mar 12, 2026

Study contacts

Merve GUMUS, Ph.D
Contact
mervedalgic10@gmail.com
00902323115619
Seda ARDAHAN SEVGİLİ, Ph.D
Contact
sedardahan@gmail.com
00902323115572
Merve GUMUS, Ph.D
principal investigator · Ege University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion